Triple Agonists: The Incretin Arms Race Explained
From semaglutide to tirzepatide to experimental triple agonists — a mechanistic breakdown of where incretin therapy is headed.
Published June 5, 2026·4 min read·Evidence: Peer Reviewed
What They Found
This review traces the evolution from single GLP-1 agonists like semaglutide to dual GLP-1/GIP agonists like tirzepatide, and previews the next wave: triple agonists targeting GLP-1, GIP, and glucagon receptors. The authors outline how each additional receptor target appears to enhance metabolic benefits beyond what single-target therapies achieve.
Why It Matters
The progression makes mechanistic sense. GLP-1 agonists work primarily through delayed gastric emptying, enhanced insulin sensitivity, and central appetite suppression. Adding GIP (glucose-dependent insulinotropic polypeptide) targeting — as tirzepatide does — appears to enhance insulin secretion and improve lipid metabolism. Clinical data shows tirzepatide consistently outperforms semaglutide for weight loss, with mean differences of 2-5 kg in head-to-head trials.
The triple agonist concept adds glucagon receptor activation, which should theoretically increase energy expenditure and enhance lipolysis. Early-phase data on compounds like retatrutide show promising signals — some participants achieving >20% weight loss in 48-week studies. The glucagon component may also improve the weight loss maintenance problem that plagues current therapies.
What's particularly interesting is how these combinations might address the metabolic flexibility issue. Pure GLP-1 agonism can reduce muscle mass alongside fat mass. Glucagon activation should preferentially target adipose tissue while preserving lean tissue through enhanced fat oxidation.
What I'd Watch For
The cardiovascular safety profile remains the critical unknown for triple agonists. Glucagon activation increases heart rate and can elevate blood pressure — effects that could offset the cardioprotective benefits we see with current GLP-1 therapies. The ongoing retatrutide cardiovascular outcomes trial won't read out for years.
I'm also watching for real-world tolerability. Each additional receptor target typically means more side effects. If triple agonists require dose escalation protocols longer than tirzepatide's already lengthy 20-week titration, clinical adoption could suffer.
Bottom Line
The mechanistic rationale for triple agonists is sound, but we're still 2-3 years from having definitive efficacy and safety data. For now, tirzepatide remains the best dual-target option, with superior weight loss compared to semaglutide in most patients. I wouldn't change current protocols based on theoretical benefits alone.